Welcome to our dedicated page for Coeptis Therapeutics SEC filings (Ticker: COEP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading a Coeptis Therapeutics filing can feel like navigating both an FDA submission and a software white paper in one sitting. Clinical trial protocols, licensing revenue waterfalls, and blockchain joint-venture details often span hundreds of pages. If you have struggled to locate when SNAP-CAR moves into Phase I or why marketing AI spend has risen, you understand the challenge.
Stock Titan resolves that pain. Our platform delivers Coeptis Therapeutics SEC filings explained simply with AI-powered summaries that surface precisely what matters. Instantly review a Coeptis Therapeutics annual report 10-K simplified to see pipeline risk factors, or open the Coeptis Therapeutics quarterly earnings report 10-Q filing for concise R&D and cash-burn highlights. Real-time alerts flag every Coeptis Therapeutics Form 4 insider transactions real-time so you never miss executive stock movements—ideal for tracking Coeptis Therapeutics executive stock transactions Form 4 ahead of clinical milestones.
All documents are updated the moment they hit EDGAR: 8-Ks for trial readouts and tech acquisitions, 13Ds for new strategic investors, and the Coeptis Therapeutics proxy statement executive compensation for insight into incentive structures. Our AI links each form to practical use cases: compare quarter-over-quarter progress with a click, analyze licensing revenue splits, or monitor Coeptis Therapeutics insider trading Form 4 transactions against upcoming FDA meetings. Need context after a surprise press release? The Coeptis Therapeutics 8-K material events explained module shows how it may impact cash runway. Whether you are focused on Coeptis Therapeutics earnings report filing analysis or just understanding Coeptis Therapeutics SEC documents with AI, Stock Titan makes the journey clear, fast, and complete.
Coeptis Therapeutics Holdings, Inc. is soliciting stockholder approval for a merger in which a wholly owned subsidiary of Coeptis will merge with and into Z Squared Inc. under a Merger Agreement dated April 25, 2025. The proxy/prospectus seeks approval for seven proposals including the Merger, a Spin Out of certain biopharmaceutical operations, a corporate name change to Z Squared Inc., a new equity incentive plan, board composition, option repricing, and an adjournment proposal. Sun Business Valuations LLC provided a fairness opinion, dated May 12, 2025, that the Merger is financially fair to Coeptis stockholders. The filing discloses a possible termination fee of $5.0 million and numerous closing conditions (antitrust, regulatory consents, Nasdaq listing continuation and SEC effectiveness).
Pro forma highlights show combined operating losses: Coeptis six-month net loss of $7.8M and Z Squared six-month net loss of $10.9M, pro forma adjustments include recognition of $63.1M goodwill/intangible uplift and the contribution of 9,000 mining machines by related party. The filing also discloses a substantial doubt about going concern and risks tied to crypto market volatility, regulatory uncertainty, dilution and possible litigation.
Form 144 notice for Coeptis Therapeutics Holdings, Inc. (COEP) reports a proposed sale of 5,000 common shares through Fidelity Brokerage Services LLC on 09/02/2025 on NASDAQ with an aggregate market value of $64,800.00. The filing shows total outstanding common shares of 4,820,317, indicating the shares to be sold are a small fraction of the outstanding stock.
The 5,000 shares were acquired on 10/31/2022 in a merger/acquisition transaction from the issuer. The filer reports no securities sold in the past three months. Several filer contact fields and issuer identification details are not provided in the content, so those specifics cannot be summarized from this document.
Coeptis Therapeutics Holdings, Inc. reported interim financials showing operating losses and financing activity. For the six months ended June 30, 2025, the Company recorded a net loss of $7,755,527 and management states these conditions raise substantial doubt about the Company’s ability to continue as a going concern. The Company completed a retrospective 20-for-1 reverse stock split, with 4,166,713 shares issued and outstanding at June 30, 2025 (4,820,317 noted as outstanding as of August 13, 2025). Debt and capital transactions were active: a $1,304,758 convertible note was converted by Yorkville (including $52,505 of accrued interest) into 233,500 shares at an average $5.81 conversion price, and the Company recognized a $906,429 gain on change in fair value of a derivative liability during the six months. The Company shows various convertible notes, a $150,000 SBA EIDL balance, warrant liabilities, investments recorded for transferred subscription receivables, and $1,344,750 of unamortized stock-based compensation for options. Management plans to raise additional equity or debt to fund operations, but states no assurance of success.
FAQ
What is the current stock price of Coeptis Therapeutics (COEP)?
What is the market cap of Coeptis Therapeutics (COEP)?
